TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04293692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 0.5\*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7
Study: NCT01587027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: Aminophylline dosage form-tablet dosage-500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: Aminophylline dosage form-tablet dosage-500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methazolamide
Description: Methazolamide dosage form-tablet dosage-250mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methazolamide
Description: Methazolamide dosage form-tablet dosage-250mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline and Methazolamide
Description: Aminophylline 500mg orally and Methazolamide 250mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline and Methazolamide
Description: Aminophylline 500mg orally and Methazolamide 250mg orally
Study: NCT01417143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258 (Dovitinib):
Description: TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
Study: NCT04294953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Each Patient will receive oral Duloxetine capsule 60mg at the night before operation(12hrs before surgery), the 2nd dose 60 mg Duloxetine capsule 1hr before operation and 3rd dose 60mg capsule after 24hrs postoperative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
Study: NCT03093376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effortful Control Camp
Description: An interactive, child-friendly camp. Effortful control (EC) camp is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 12 different exercises that teach inhibitory and attentional control, as well as visuospatial and working memory skills, will be administered.~Tasks will allow for scaffolding (Halperin et al, 2013), or incremental increases in difficulty of the games over time. EC camp will occur over 4 mornings from 9AM to 12PM, on two consecutive weekends.
Study: NCT02957851

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical Air

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMONO
Study: NCT00504998

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study: NCT04063475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyanoacrylate tissue adhesive beside sutures
Description: using cyanoacrylate tissue adhesive for FGG fixation
Study: NCT04116580

Intervention type: OTHER
Intervention: RAAP - for Raw Apple in connection with re-contact with the raw apple according to an Ultra-Rush protocol
Study: NCT04245774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine/Dextrose
Description: 7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
Study: NCT02510339

Intervention type: OTHER
Intervention: Observation
Description: Administration of two questionnairs during post operative visits.
Study: NCT03991533

Intervention type: OTHER
Intervention: multiparametric MRI
Description: preoperative multiparametric MRI

Intervention type: OTHER
Intervention: multiparametric MRI
Description: preoperative multiparametric MRI
Study: NCT01220791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In vitro fertilization treatment for infertility
Description: IVF treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: In vitro fertilization treatment for infertility
Description: IVF treatment
Study: NCT03273855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: fecal microbiota transplantation
Description: The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
Study: NCT01824667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-GOS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT02426099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose spironolactone
Description: 4-week add-on low dose spironolactone in resistant hypertension

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine intensification of antihypertensive treatment
Description: 4-week guidelines oriented intensification of antihypertensive treatment
Study: NCT04050033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evoke Device
Description: Subjects will undergo treatment with Evoke Device
Study: NCT02396667

Intervention type: OTHER
Intervention: 5D ultrasound
Description: Measure the femur length by 5DLB to calculate fetal weight
Study: NCT01858961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: Twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon
Description: Once a week
Study: NCT02144701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis was not performed because of no differences in the clinical outcomes
Description: Correlative studies
Study: NCT00581191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once
Study: NCT03207451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Vorapaxar is the principle study drug and will be given to all subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar and Aspirin
Description: Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar and Clopidogrel
Description: Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar, Aspirin, and Clopidogrel
Description: Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
Study: NCT03170895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma
Study: NCT01218802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10 mg. daily for 96 weeks
Description: Participants will take Rosuvastatin 10 mg. daily for 96 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will take a sugar pill daily for 96 weeks
Study: NCT03170895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine Mepesuccinate Injection
Description: Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
Study: NCT01244178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Intravenous Hyperinsulinemic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Intravenous Hyperinsulinemic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Standard Intravenous Insulin Therapy
Study: NCT02656030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semispinalis cervicis resisted exercise
Description: semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cranio-cervical flexion exercise
Description: cranio-cervical flexion exercise, 2 time per week, 6 weeks duration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care, 2 time per week, 6 weeks duration
Study: NCT00523432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Weekly doses via IV infusion. Dose will be assigned based on time of study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Weekly doses via IV infusion. Dose will be assigned based on time of study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779 (temsirolimus)
Description: Weekly 25mg dose via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779 (temsirolimus)
Description: Weekly 25mg dose via IV infusion.
Study: NCT04151511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Erector Spinae Plane Block
Description: 1. Continuous Thoracic Epidural Thoracic Epidural Analgesia~2. Continuous Erector Spinae Plane Block

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Continuous Erector Spinae Plane Block
Description: 1. Continuous Thoracic Epidural Thoracic Epidural Analgesia~2. Continuous Erector Spinae Plane Block
Study: NCT02462265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D & Oshadi R;
Description: Oshadi D (180mg/TID) \& Oshadi R (180mg TID) will be administrated;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvage therapy cytosar and mitoxantrone
Description: Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
Study: NCT02123381

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative radiotherapy
Description: Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
Study: NCT01894906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble Ferric Pyrophosphate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00976339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.
Study: NCT02944175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
Study: NCT01231269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan without administration of contrast/without radiation
Study: NCT02723240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373
Study: NCT02933853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
Study: NCT01356420

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholesterol supplementation
Description: Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
Study: NCT05975489

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute caffeine supplementation
Description: To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute caffeine supplementation
Description: To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute caffeine supplementation
Description: To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women
Study: NCT03137810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placental cord drainage
Description: In the study group a of total number of 90 women placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.~Blood loss in the third stage will be measured using a Kelly's pad which will be used during delivery and the blood lost will be collected in a clean metal bowl which will be kept at the tail end of Kelley's pad.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non placemtal cord drainage
Description: In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
Study: NCT03627104

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Normoprotein diet with animal protein
Description: Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Normoprotein diet with vegetable protein
Description: Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-protein diet with animal protein
Description: Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-protein diet with vegetable protein
Description: ach patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
Study: NCT02930694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (capsule)
Description: Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (capsule)
Description: Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (capsule)
Description: Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (capsule)
Description: Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (suspension)
Description: Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (suspension)
Description: Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (suspension)
Description: Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (suspension)
Description: Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
Study: NCT03043053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin nasal spray
Description: oxytocin intranasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study: NCT03023995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF with Platelet rich fibrin
Description: In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it and secured with 4-0 non resorbable sutures.
Study: NCT03433508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liberal
Description: 2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive
Description: To maintain the target Hemoglobin of 7 to 8 gm/dL.